Technical Analysis for WVE - WAVE Life Sciences Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 4.87 | 1.46% | 0.07 |
Earnings due: May 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 1.46% | |
Lower Bollinger Band Walk | Weakness | 1.46% | |
Below Lower BB | Weakness | 1.46% | |
Oversold Stochastic | Weakness | 1.46% | |
Fell Below 200 DMA | Bearish | 1.67% | |
MACD Bearish Centerline Cross | Bearish | 1.67% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 19 hours ago |
Down 1% | about 19 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Rose Above Lower Bollinger Band | about 22 hours ago |
Up 3% | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/01/2024
WAVE Life Sciences Ltd. Description
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Rare Diseases Medical Genetics Dysfunction Inflammatory Bowel Disease Dystrophy Muscular Dystrophy Huntington's Disease Duchenne Muscular Dystrophy Genodermatoses Duchenne Epidermolysis Bullosa Genetic Genealogy Cytoskeleton Dystrophin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.6699 |
52 Week Low | 3.1501 |
Average Volume | 929,248 |
200-Day Moving Average | 5.04 |
50-Day Moving Average | 5.39 |
20-Day Moving Average | 5.73 |
10-Day Moving Average | 5.49 |
Average True Range | 0.39 |
RSI (14) | 35.48 |
ADX | 23.07 |
+DI | 13.34 |
-DI | 29.66 |
Chandelier Exit (Long, 3 ATRs) | 5.16 |
Chandelier Exit (Short, 3 ATRs) | 5.82 |
Upper Bollinger Bands | 6.61 |
Lower Bollinger Band | 4.85 |
Percent B (%b) | 0.01 |
BandWidth | 30.80 |
MACD Line | -0.17 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.1712 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.29 | ||||
Resistance 3 (R3) | 5.29 | 5.14 | 5.22 | ||
Resistance 2 (R2) | 5.14 | 5.04 | 5.15 | 5.20 | |
Resistance 1 (R1) | 5.01 | 4.97 | 5.08 | 5.01 | 5.17 |
Pivot Point | 4.86 | 4.86 | 4.90 | 4.87 | 4.86 |
Support 1 (S1) | 4.73 | 4.76 | 4.80 | 4.73 | 4.57 |
Support 2 (S2) | 4.58 | 4.69 | 4.59 | 4.54 | |
Support 3 (S3) | 4.45 | 4.58 | 4.52 | ||
Support 4 (S4) | 4.45 |